1
NR546 PSYCHOPHARMACOLOGY FOR PMHNP MIDTERM
EXAM 2026/2027 | NEW UPDATED EDITION | Chamberlain
University | Questions & Verified Answers | Pass Guaranteed
- A+ Graded
Section 1: Neurobiology & Receptor Mechanisms - NEW 2026 Insights (Questions
1-12)
Q1. Esketamine (Spravato) produces rapid antidepressant effects primarily through
which neurobiological mechanism?
A. Selective serotonin reuptake inhibition
B. NMDA receptor antagonism with downstream glutamate surge and synaptic
plasticity enhancement
C. Dopamine D2 receptor partial agonism
D. GABA-A receptor positive allosteric modulation
B. NMDA receptor antagonism with downstream glutamate surge and synaptic
plasticity enhancement [CORRECT]
Rationale: Esketamine is the S-enantiomer of ketamine and acts as a non-competitive
NMDA receptor antagonist. This triggers a glutamate surge activating AMPA
receptors, promoting BDNF release and synaptogenesis. This mechanism is distinct
from monoamine-based antidepressants. Per 2026 REMS updates, administration
requires direct observation.
Correct Answer: B
Q2. Zuranolone (Zurzuvae) is a novel agent FDA-approved in 2023 for postpartum
depression. Its mechanism involves modulation of which receptor system?
A. NMDA receptor
B. GABA-A receptor positive allosteric modulation via neurosteroid binding at distinct
,2
sites
C. 5-HT1A receptor partial agonism
D. Dopamine transporter inhibition
B. GABA-A receptor positive allosteric modulation via neurosteroid binding at distinct
sites [CORRECT]
Rationale: Zuranolone is an oral neuroactive steroid that modulates GABA-A
receptors at distinct allosteric sites different from benzodiazepines. It is FDA-
approved for postpartum depression with a 14-day oral course. Unlike brexanolone
(IV), zuranolone offers oral administration convenience.
Correct Answer: B
Q3. Brexanolone (Zulresso) differs from zuranolone (Zurzuvae) in which critical
clinical parameter?
A. Brexanolone is oral; zuranolone requires 60-hour IV infusion
B. Brexanolone requires a 60-hour IV infusion with REMS-certified healthcare facility
monitoring; zuranolone is oral and self-administered
C. Both are oral agents with identical administration requirements
D. Brexanolone is a benzodiazepine; zuranolone is an SSRI
B. Brexanolone requires a 60-hour IV infusion with REMS-certified healthcare facility
monitoring; zuranolone is oral and self-administered [CORRECT]
Rationale: Brexanolone requires a 60-hour continuous IV infusion in a REMS-certified
healthcare facility with continuous pulse oximetry due to risk of excessive sedation
and sudden loss of consciousness. Zuranolone is an oral 14-day course that can be
taken at home.
Correct Answer: B
Q4. Vortioxetine (Trintellix) is described as a "multimodal" antidepressant because it:
,3
A. Inhibits serotonin reuptake and modulates multiple serotonin receptors (5-HT1A
partial agonism, 5-HT1B partial agonism, 5-HT3 antagonism, 5-HT7 antagonism)
B. Blocks both serotonin and norepinephrine reuptake equally
C. Acts as a dopamine reuptake inhibitor only
D. Is a combination of an SSRI and a benzodiazepine
A. Inhibits serotonin reuptake and modulates multiple serotonin receptors (5-HT1A
partial agonism, 5-HT1B partial agonism, 5-HT3 antagonism, 5-HT7 antagonism)
[CORRECT]
Rationale: Vortioxetine's multimodal mechanism includes SERT inhibition plus 5-
HT1A partial agonism, 5-HT1B partial agonism, 5-HT3 antagonism, and 5-HT7
antagonism. This receptor profile is associated with cognitive benefits in depression,
distinguishing it from pure SSRIs.
Correct Answer: A
Q5. Vilazodone (Viibryd) combines SSRI activity with which additional receptor
mechanism?
A. 5-HT1A receptor partial agonism
B. 5-HT2A receptor antagonism
C. Norepinephrine reuptake inhibition
D. Dopamine D2 receptor antagonism
A. 5-HT1A receptor partial agonism [CORRECT]
Rationale: Vilazodone is a selective serotonin reuptake inhibitor and 5-HT1A receptor
partial agonist. The 5-HT1A partial agonism may contribute to anxiolytic effects and
mitigate SSRI-induced sexual dysfunction, though it requires administration with
food for adequate absorption.
Correct Answer: A
, 4
Q6. A patient with treatment-resistant depression is being considered for esketamine
(Spravato). Which statement accurately reflects the 2026 REMS program
requirements?
A. Esketamine can be prescribed for at-home self-administration
B. Esketamine must be administered in a certified healthcare setting with direct
patient observation for 2 hours post-dose, and a REMS registry is required
C. Esketamine requires only a 30-minute observation period
D. No REMS program is required for esketamine
B. Esketamine must be administered in a certified healthcare setting with direct
patient observation for 2 hours post-dose, and a REMS registry is required
[CORRECT]
Rationale: Per 2026 REMS updates, esketamine requires administration in a certified
healthcare setting with direct observation for at least 2 hours post-dose due to risks
of dissociation, sedation, and blood pressure elevation. The REMS program mandates
healthcare facility certification and patient monitoring.
Correct Answer: B
Q7. The glutamate hypothesis of depression proposes that dysfunction in which
receptor system contributes to depressive pathophysiology and is targeted by novel
rapid-acting antidepressants?
A. GABA-B receptors
B. NMDA receptors and downstream AMPA receptor activation
C. Muscarinic acetylcholine receptors
D. Histamine H1 receptors
B. NMDA receptors and downstream AMPA receptor activation [CORRECT]
Rationale: The glutamate hypothesis posits that NMDA receptor hypofunction and
reduced AMPA receptor signaling contribute to synaptic atrophy in depression.
Ketamine and esketamine produce rapid antidepressant effects by transiently
blocking NMDA receptors, triggering AMPA-mediated synaptic plasticity.
Correct Answer: B
NR546 PSYCHOPHARMACOLOGY FOR PMHNP MIDTERM
EXAM 2026/2027 | NEW UPDATED EDITION | Chamberlain
University | Questions & Verified Answers | Pass Guaranteed
- A+ Graded
Section 1: Neurobiology & Receptor Mechanisms - NEW 2026 Insights (Questions
1-12)
Q1. Esketamine (Spravato) produces rapid antidepressant effects primarily through
which neurobiological mechanism?
A. Selective serotonin reuptake inhibition
B. NMDA receptor antagonism with downstream glutamate surge and synaptic
plasticity enhancement
C. Dopamine D2 receptor partial agonism
D. GABA-A receptor positive allosteric modulation
B. NMDA receptor antagonism with downstream glutamate surge and synaptic
plasticity enhancement [CORRECT]
Rationale: Esketamine is the S-enantiomer of ketamine and acts as a non-competitive
NMDA receptor antagonist. This triggers a glutamate surge activating AMPA
receptors, promoting BDNF release and synaptogenesis. This mechanism is distinct
from monoamine-based antidepressants. Per 2026 REMS updates, administration
requires direct observation.
Correct Answer: B
Q2. Zuranolone (Zurzuvae) is a novel agent FDA-approved in 2023 for postpartum
depression. Its mechanism involves modulation of which receptor system?
A. NMDA receptor
B. GABA-A receptor positive allosteric modulation via neurosteroid binding at distinct
,2
sites
C. 5-HT1A receptor partial agonism
D. Dopamine transporter inhibition
B. GABA-A receptor positive allosteric modulation via neurosteroid binding at distinct
sites [CORRECT]
Rationale: Zuranolone is an oral neuroactive steroid that modulates GABA-A
receptors at distinct allosteric sites different from benzodiazepines. It is FDA-
approved for postpartum depression with a 14-day oral course. Unlike brexanolone
(IV), zuranolone offers oral administration convenience.
Correct Answer: B
Q3. Brexanolone (Zulresso) differs from zuranolone (Zurzuvae) in which critical
clinical parameter?
A. Brexanolone is oral; zuranolone requires 60-hour IV infusion
B. Brexanolone requires a 60-hour IV infusion with REMS-certified healthcare facility
monitoring; zuranolone is oral and self-administered
C. Both are oral agents with identical administration requirements
D. Brexanolone is a benzodiazepine; zuranolone is an SSRI
B. Brexanolone requires a 60-hour IV infusion with REMS-certified healthcare facility
monitoring; zuranolone is oral and self-administered [CORRECT]
Rationale: Brexanolone requires a 60-hour continuous IV infusion in a REMS-certified
healthcare facility with continuous pulse oximetry due to risk of excessive sedation
and sudden loss of consciousness. Zuranolone is an oral 14-day course that can be
taken at home.
Correct Answer: B
Q4. Vortioxetine (Trintellix) is described as a "multimodal" antidepressant because it:
,3
A. Inhibits serotonin reuptake and modulates multiple serotonin receptors (5-HT1A
partial agonism, 5-HT1B partial agonism, 5-HT3 antagonism, 5-HT7 antagonism)
B. Blocks both serotonin and norepinephrine reuptake equally
C. Acts as a dopamine reuptake inhibitor only
D. Is a combination of an SSRI and a benzodiazepine
A. Inhibits serotonin reuptake and modulates multiple serotonin receptors (5-HT1A
partial agonism, 5-HT1B partial agonism, 5-HT3 antagonism, 5-HT7 antagonism)
[CORRECT]
Rationale: Vortioxetine's multimodal mechanism includes SERT inhibition plus 5-
HT1A partial agonism, 5-HT1B partial agonism, 5-HT3 antagonism, and 5-HT7
antagonism. This receptor profile is associated with cognitive benefits in depression,
distinguishing it from pure SSRIs.
Correct Answer: A
Q5. Vilazodone (Viibryd) combines SSRI activity with which additional receptor
mechanism?
A. 5-HT1A receptor partial agonism
B. 5-HT2A receptor antagonism
C. Norepinephrine reuptake inhibition
D. Dopamine D2 receptor antagonism
A. 5-HT1A receptor partial agonism [CORRECT]
Rationale: Vilazodone is a selective serotonin reuptake inhibitor and 5-HT1A receptor
partial agonist. The 5-HT1A partial agonism may contribute to anxiolytic effects and
mitigate SSRI-induced sexual dysfunction, though it requires administration with
food for adequate absorption.
Correct Answer: A
, 4
Q6. A patient with treatment-resistant depression is being considered for esketamine
(Spravato). Which statement accurately reflects the 2026 REMS program
requirements?
A. Esketamine can be prescribed for at-home self-administration
B. Esketamine must be administered in a certified healthcare setting with direct
patient observation for 2 hours post-dose, and a REMS registry is required
C. Esketamine requires only a 30-minute observation period
D. No REMS program is required for esketamine
B. Esketamine must be administered in a certified healthcare setting with direct
patient observation for 2 hours post-dose, and a REMS registry is required
[CORRECT]
Rationale: Per 2026 REMS updates, esketamine requires administration in a certified
healthcare setting with direct observation for at least 2 hours post-dose due to risks
of dissociation, sedation, and blood pressure elevation. The REMS program mandates
healthcare facility certification and patient monitoring.
Correct Answer: B
Q7. The glutamate hypothesis of depression proposes that dysfunction in which
receptor system contributes to depressive pathophysiology and is targeted by novel
rapid-acting antidepressants?
A. GABA-B receptors
B. NMDA receptors and downstream AMPA receptor activation
C. Muscarinic acetylcholine receptors
D. Histamine H1 receptors
B. NMDA receptors and downstream AMPA receptor activation [CORRECT]
Rationale: The glutamate hypothesis posits that NMDA receptor hypofunction and
reduced AMPA receptor signaling contribute to synaptic atrophy in depression.
Ketamine and esketamine produce rapid antidepressant effects by transiently
blocking NMDA receptors, triggering AMPA-mediated synaptic plasticity.
Correct Answer: B
